Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 8/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 8/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881105 | 0.79 | ACLY (0.49) | ACLYPTGES2LGALS8LGALS3LGALS1 | |
| SCHEMBL21612475 | 0.78 | PTGER3 (0.47) | PTGER3 | |
| SCHEMBL21612473 | 0.78 | PTGER3 (0.47) | PTGER3 | |
| SCHEMBL12228293 | 0.76 | PTGES2 (0.49) | ACLYPTGES2LGALS8LGALS3LGALS1 | |
| SCHEMBL31487939 | 0.76 | FLT1 (0.63) | — | |
| SCHEMBL6261295 | 0.76 | PTGES2 (0.53) | ACLYPTGES2LGALS8LGALS3LGALS1 | |
| SCHEMBL194745 | 0.73 | MAPT (0.53) | PTGES2FBP1 | |
| SCHEMBL1137435 | 0.72 | DAO (0.43) | ACLYPTGES2LGALS8LGALS3LGALS1 | |
| SCHEMBL8300222 | 0.72 | PTGES2 (0.43) | ACLYPTGES2LGALS8LGALS3CCR4 | |
| SCHEMBL3483871 | 0.72 | PFKFB4 (0.36) | ACLYDAOPTGER3FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| WO-2020008317-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, FFAR3, PTGES3 | ACLY 1327/4885PTGES2 30/4885LGALS8 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.